Indications for RETROVIR IV:
HIV infection. Prevention of maternal-fetal HIV transmission.
Adult Dose for RETROVIR IV:
Give by IV infusion over 1 hour; use only until oral therapy can be given. 1mg/kg 5–6 times daily. End-stage renal disease on dialysis: 1mg/kg every 6–8 hours. Vertical transmission, severe anemia and/or neutropenia: see literature.
Children's Dose for RETROVIR IV:
Vertical transmission: see literature.
See Also:
RETROVIR CAPSULES
RETROVIR SYRUP
RETROVIR TABLETS
Pharmacological Class:
Nucleoside analogue (reverse transcriptase inhibitor).
Warnings/Precautions:
Suspend if lactic acidosis or hepatotoxicity (eg, hepatomegaly, steatosis) occurs. Monitor for hematologic toxicity; reduce dose or suspend if significant anemia and/or granulocytopenia occurs; transfuse if necessary. Renal or hepatic dysfunction: consider reducing dose. Bone marrow suppression. Risk of liver disease. Women, obesity, prolonged nucleoside exposure, or advanced HIV disease: increased risk of toxicity. Elderly. Pregnancy (Cat.C). Nursing mothers: not recommended.
Interactions:
Avoid stavudine, doxorubicin, ribavirin, other nucleoside analogues, other forms of zidovudine. Caution with other cytotoxic or myelosuppressive drugs (eg, ganciclovir, interferon-alpha, ribavirin). Fluconazole, atovaquone, lamivudine, probenecid, valproic acid, methadone increase zidovudine levels. Monitor phenytoin. May be antagonized by rifampin, ritonavir, nelfinavir. Monitor for treatment-associated toxicities with interferon-alpha with or without ribavirin.
Adverse Reactions:
Anemia, neutropenia, headache, malaise, GI disturbances, insomnia, pain, myopathy, neuropathy, myositis, thrombocytopenia, lactic acidosis, steatosis, hepatomegaly, fat redistribution, immune reconstitution syndrome, pancreatitis, others. Children: also fever, cough.
Note:
Register pregnant patients exposed to zidovudine by calling (800) 258-4263.
How Supplied:
Tabs—60; Caps—100; Syrup—240mL; IV (20mL/vial)—10
